It is estimated that about 17% of individuals with taijin kyofusho have fears of releasing foul body odor. See also
Anthropophobia
Avoidant personality disorder
Hikikomori
NEET
Obsessive–compulsive disorder

References
Further reading
Suzuki, K. (2003). "Is Taijin Kyofusho a Culture-Bound Syndrome?". American Journal of Psychiatry. 160 (7): 1358. doi:10.1176/appi.ajp.160.7.1358. PMID 12832264. Maeda, F; Nathan, JH (1999). "Understanding taijin kyofusho through its treatment, Morita therapy". Journal of Psychosomatic Research. 46 (6): 525–30. doi:10.1016/S0022-3999(98)00113-5. PMID 10454167. Matsunaga, Hisato; Kiriike, Nobuo; Matsui, Tokuzo; Iwasaki, Yoko; Stein, Dan J. (2001). "Taijin kyofusho: A form of social anxiety disorder that responds to serotonin reuptake inhibitors?". The International Journal of Neuropsychopharmacology. 4 (3): 231–7. doi:10.1017/S1461145701002474. PMID 11602029. Nagata T.; Oshima J.; Wada A.; Yamada H.; Iketani T.; Kiriike N. (2003). "Open trial of milnacipran for Taijin-Kyofusho in Japanese patients with social anxiety disorder". International Journal of Psychiatry in Clinical Practice. 7 (2): 107–112. doi:10.1080/13651500310000690. External links
Support Group Providers for Social Phobia  Taijin kyofusho at Curlie
http://www.japanpowered.com/japan-culture/taijin-kyofusho-the-disorder-of-fear
http://anthropology.msu.edu/anp204-us12/2012/07/20/taijin-kyofusho-in-japan-and-south-korea/
McNally, Richard J.; Cassiday, Karen L.; Calamari, John E. (January 1990). "Taijin-kyofu-sho in a black American woman: Behavioral treatment of a "culture-bound" anxiety disorder". Journal of Anxiety Disorders. 4 (1): 83–87. doi:10.1016/0887-6185(90)90025-5.
http://www.stolaf.edu/depts/ciswp/khughes/papers/psychopathology.pdf
http://jcc.sagepub.com/content/43/2/219.abstract
Taliglucerase alfa, sold under the brand name Elelyso among others, is a biopharmaceutical medication developed by Protalix and Pfizer. The drug, a recombinant glucocerebrosidase used to treat Gauchers disease, is the first plant-made pharmaceutical to win approval by the U.S. Food and Drug Administration (FDA). Each vial has 200 units of taliglucerase alfa. Approval history
The U.S. FDA New Drug Application (NDA) was granted approval in May 2012, for use in adults. The U.S. FDA Supplemental New Drug Application (sNDA) for pediatric use was granted approved in August 2014. In Israel, the Israeli Ministry of Health granted approval in September 2012. In Brazil, the Brazilian Health Surveillance Agency (ANVISA) granted approval in March 2013. In Canada, Health Canada issued a Notice of Compliance in May 2014, for both adults and pediatric patients.Taliglucerase alfa is made by the Israeli biotherapeutics company Protalix and sold by the American pharmaceutical company Pfizer. Society and culture
Economics
For 2016, Elelyso was ranked third for pharmaceuticals with the highest cost-per-patient, with an average cost of $483,242 per year. References
External links
"Taliglucerase alfa". Drug Information Portal. U.S. National Library of Medicine.